PIM1 Antibodies

Serine/threonine-protein kinase pim-1 (PIM1)

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and so providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3).

Phosphorylation of MYC contributes to a rise of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis.

Gene Information

Human
Gene Name:	PIM1
Uniprot:	P11309
Entrez:	5292

Family

Belongs to:
protein kinase superfamily

Alternative Names

EC 2.7.11.1; Oncogene PIM1; PIM; pim-1 kinase 44 kDa isoform; pim-1 oncogene (proviral integration site 1); pim-1 oncogene; PIM1; proto-oncogene serine/threonine-protein kinase pim-1

Molecular Weight

Mass (kDA):
35.686 kDA

Genomic Context

Human
Location:	6p21.2
Sequence:	6; NC_000006.12 (37170152..37175428)

Tissue Specificity

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines.

Subcellular Localizations

[Isoform 1]: Cytoplasm. Nucleus.; [Isoform 2]: Cell membrane.

Diseases

• Neoplasms
• Malignant Neoplasms
• Lymphoma
• Leukemia
• Cell Transformation, Neoplastic
• Leukemogenesis
• Malignant Neoplasm Of Prostate
• Prostatic Neoplasms
• T-cell Lymphoma
• Myeloid Leukemia
• B-cell Lymphomas
• Malignant Paraganglionic Neoplasm

• Carcinoma
• Leukemia, Myelocytic, Acute
• Diffuse Large B-cell Lymphoma
• Genomic Instability
• Inflammation
• Tumor Progression
• Hematopoietic Neoplasms

Interacting Proteins

• ABCG2
• BANP
• BMX
• CDKN1B
• FH

• FOXO3
• FXR2
• HEXIM2
• PRKCA
• RPS19

• ZBTB1

Pathways

• Cell Cycle
• Cell Proliferation
• Cell Growth
• Pathogenesis
• Cell Death
• Translation
• Mitosis
• Localization
• Rna Interference
• Proteolysis
• Dna Replication
• Transport
• Oncogenesis

• Nuclear Export
• Cell Differentiation
• Angiogenesis
• Drug Resistance
• Cytokinesis
• Cell Division
• Protein Import

PTMs

• Phosphorylation
• Cleavage
• Reduction
• Deamination

• Glycosylation
• Acylation
• Acetylation
• Dephosphorylation

• Methylation

Research Areas

• Cancer
• Protein Kinase
• Tumor Suppressors

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PIM1

Boster Bio: Best Uses Of The PIM1 Marker

If you're searching for a new marker to identify DNA fragments, you should read about the benefits of the Boster Bio: PIM1 marker. This marker has many advantages, including its efficacy and affordable price. But is it worth the cost? This article will examine the costs and benefits of this product, as and clinical applications. It is a useful instrument for any scientist, and is useful to all scientists around the world.

Benefits

The PIM1 marker is a possible candidate for treatment for breast cancer. It has been proven to play a key role in the development of breast cancer. In a study it was found that PIM1 upregulation was linked to a high tumor grade. Researchers also discovered that PIM1 was a factor in the development of breast cancer cells. The PIM1 gene is involved in the EMT and stemness processes of cancer cells.

In the case of pulmonary arterial hypertension (PAH) In PAH, the PIM1 gene is elevated. This is due to its involvement in many prosurvival pathways. PIM1 inhibitors inhibit DNA damage response , and thus prevent cell death. They are effective in treating PAH because they target multiple pathways. Below are some benefits of the PIM1 marker for PAH patients. The advantages of the PIM1 marker are numerous.

The PIM1 gene plays a key role in suppressive neutrophil function. It is associated with less suppressive neutrophils. This may explain its beneficial effects in cancer and chronic viral infections. Additionally, PIM kinase inhibitors also reduce the number of neutrophils in suppressive and monocytes and suppressive neutrophils, which are alike in metabolic condition. They may even play a role in suppressive functions.

Cancer is also associated with the PIM1 gene. Studies have shown that PIM1 can be overexpressed in some types of cancer. It can also be used as a biomarker to detect cancer. PIM1 inhibitors upregulate p27 expression and suppress tumor formation. The advantages of the PIM1 marker are being explored, however. Recent studies have demonstrated that PIM1 may play an important role in breast cancer prevention.

Treatments that induced DNA damage inhibited PIM1 and decreased the expression of gH2AX. These results suggest that PIM1 may be involved in the primary events that repair DNA damage before H2AX protein protein phosphorylation. It could also play an important role in DNA damage recognition. This could be the reason why PIM1 may be a promising candidate for treatment of cancer. The question is what is the best way to target this gene?

Clinical applications

Recent research has revealed that PIM1 plays a significant role in cancer cell growth. PIM1 helps to prolong the life of cells and prevents apoptosis by the prevention of the loss of growth factors essential to growth. The PIM1 gene was first discovered to increase the survival of cells in myeloid cells that are dependent on IL-3. When the cells were depleted of IL-3, PIM1-expressing cells lived longer than the cells who did not have PIM1.

In this study, the PIM1 protein expression was determined by immunohistochemistry. PIM1 protein expression was higher in 72% of mantle cells cancer cases. A lower chance of survival for patients is associated with higher levels of this protein. These results suggest that PIM1 might be an effective prognostic marker for patients suffering from gastric cancer. Further studies are required to determine whether the PIM1 protein is useful in determining the outcome of patients.

The PIM1 marker can be used in the diagnosis of cancer and treatment. The detection of the PIM1 gene in tumors will enable doctors to tailor treatment to the specific needs of the patient. A combination of inhibitors can be used to target the proteins involved in tumor growth. PIM1 is the most well-known target, but Hsp90 is also a possible target. Low-level chemotherapy can also be used to reduce PIM1 activity.

Bcl-2 is an antiapoptotic protein that inhibits the cell death process. PIM1 can phosphorylate BAD on Ser112 which is the gatekeeper for BAD activation. BAD can interact with other members of the Bcl-2 family including Bclxl, an antiapoptotic prot. It is therefore essential to know that the PIM1 gene is closely related to the Bcl-2 gene.

The PIM1 gene regulates many proteins that play a role in the advancement of cancer. One of them is PIM1 is essential in controlling cell proliferation and inhibiting the process of apoptosis. This gene has been the subject of extensive research and the development of therapies based on the findings. The research is ongoing to better understand the role PIM1 plays in the treatment of cancer. It is an intriguing candidate for clinical trials.

Efficacy

The tumor suppressor gene PIM1 is used to detect tumor Adenocarcinomas. Patients suffering from INSS stage 4 and other high-risk conditions have significantly higher levels of this gene. In our study, PIM1 expression levels in the tumor tissues were evaluated by determining the percentage of cells that were positive for the marker. The Cell Counting Kit-8 (8 (CCK-8) is a reagent used to measure the expression levels. The reagent is added to the sample for two days. We measured the optical density at 450nm.

It is not known what PIM-1 does to patients suffering from pancreatic cancer. A recent study has proven that prostate cancer cells are more tolerant to chemotherapy when this protein is downregulated. Pgp is protected by PIM-1, which permits glycosylation and translocation on the cell's surface. These studies support the role of PIM-1 in pancreatic carcinoma but don't provide a detailed explanation of how the protein affects the sensitivity of chemotherapy drugs or the expression of pancreatic tumor stem cells.

Additionally, PIM1 levels were higher in patients with pancreatic cancer than in any other control subjects. Patients with pancreatic cancer had a median PIM-1 level of 29.8 +/ 47.7 ng/ml higher than subjects. This suggests that the PIM1 marker could be a brand new marker for pancreatic cancer patients. This suggests that PIM1 may be a novel therapeutic target for ATL.

We have previously identified isolated metabolites that inhibit Pim-1 kinase and we discovered that these compounds block the enzyme that is activated by Pim-1 kinase. Two compounds showed the strongest inhibitory effects, which we were able to identify. These two compounds inhibit HT-29 and HL-60 cells. These compounds have dramatic effects on cancer cells. They are promising targets for the development of innovative therapeutics.

Cost

The PIM1 marker is a protein that is expressed in many human cells. The 44 kDa PIM1 protein is found primarily on the plasma membrane. However, the 33kDa PIM1 protein is found in the cytosol as well as the nucleus. The two markers have different roles in the progression of tumors. It is crucial to know the role of PIM1 during the course of development of cancer in order to treat this disease. The cost of PIM1 is too high.

The PIM1 protein is a serine/threonine Kinase encoded by the Provirus integration site of the Moloney murine leukemia virus. The protein plays an important role in the progression of malignancies. PIM1 antibodies recognize PIM-1 in the nucleus of human cancer cells and in the cytosol. The antibodies used for PIM1 analysis are made from rabbit anti-PIM-1.